For instance, in glioblastoma, NDR1 has been reported to phosphorylate YAP, thereby suppressing its oncogenic activity and exerting a tumor-suppressive effect (Chen et al., 2021); in colorectal cancer, loss of NDR1/2 correlates with YAP dephosphorylation, leading to uncontrolled cell proliferation and carcinogenesis (Zhang et al., 2015); in prostate cancer, NDR1 appears to inhibit tumor metastasis through crosstalk with the Wnt pathway (Xuan et al., 2024), although its impact on tumor immunity manifests as a pro-tumorigenic effect (Fu et al., 2024). The gene discussed is YAP1; the disease is prostate cancer.